Search In this Thesis
   Search In this Thesis  
العنوان
Rapid and Sustained Virologic Response of Triple Therapy in Egyptian Patients with chronic Hepatitis C Virus Infection/
المؤلف
Fily,Amir Samy
هيئة الاعداد
باحث / أمير سامى فلى
مشرف / محمد كمال شاكر
مشرف / فاطمة احمد على الدين
مشرف / مى اسماعيل محرز
تاريخ النشر
2016.
عدد الصفحات
144.p;
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الطب (متفرقات)
تاريخ الإجازة
1/10/2016
مكان الإجازة
جامعة عين شمس - كلية الطب - Tropical Medicine
الفهرس
Only 14 pages are availabe for public view

from 144

from 144

Abstract

Objective: to assess the prevalence of rapid and sustained virologic response to triple therapy (interferon, ribavirin and sofosbuvir) in Egyptian patients with chronic hepatitis C virus infection comparing patients who had previous interferon based trials and naive patients.
Study design: Prospective randomized controlled trial.
Study setting: National Hepatology and Tropical Medicine Research Institute.
Patients: The study included 200 consecutive chronic HCV patients who were proved to be cirrhotic (F3-F4) by liver biopsy, fibroscan or FIB4 score. They were divided into two groups, patients had experienced IFN therapy before and naïve patients , HCV PCR had been done for all patients after 4 weeks ,at end of treatment (12 weeks of treatment with triple therapy) and after 12 weeks after end of treatment to compare rapid and sustained viral response between naive and experienced treated patients.
Results: Rapid viral response of all the studied patients was 77.8%, in the naïve patients was77. 2 % , in the non-responder patients was 61.8% , in the patients with previous breakthrough was79.2% and it was 90.9 % in the relapser patients. At end of the treatment, HCV RNA by PCR was negative in all patients except only 2 patients (99%) one of them was from the non-responder group while the other one was from the break through group .SVR was 78.5% in the all studied patients , SVR in naïve patients was 84%, SVR in the non-responder patients was 58.8%, and SVR in the patient with breakthrough was 69.9 %, while SVR in the relapser patients was 86%.
Conclusion: Rapid, sustained and end of treatment response in our study are similar in the naïve and interferon experienced patients.Rates of SVR is significantly lower in the non-responder (58.8%) compared to the other groups (naïve 84%, breakthrough 69.9%, relapse 86%).The SVR rate in our study is less than other studies with the same regimens of treatment. Factors contributed to this difference need further studies.